An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST) Refractory to, Intolerant of, or Not a Candidate for Imatinib and Sunitinib Treatment.

Trial Profile

An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST) Refractory to, Intolerant of, or Not a Candidate for Imatinib and Sunitinib Treatment.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2015

At a glance

  • Drugs CNF 2024 (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Pharmacodynamics
  • Sponsors Biogen Idec
  • Most Recent Events

    • 19 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Jan 2010 Planned end date changed from 1 Jan 2010 to 1 Apr 2010 as reported by ClinicalTrials.gov.
    • 02 May 2009 Additional trial centre/investigator Keedy, Vicki reported by Vanderbilt-Ingram Cancer Center.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top